彩盈彩票

Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 3 drugs approved in the U.S. Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.
Drug
Indication
Topic
ZL-2306 (Niraparib)
Ovarian Cancer
To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of platinum-sensitive recurrent ovarian cancer
ZL-2306 (Niraparib)
Ovarian Cancer
To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of ovarian cancer patients who were responsive to first-line chemotherapy
FPA-144
Gastric Cancer & Gastroesophageal Cancer
Evaluation of I/III randomized controlled trial of FPA144 combined with FOLFOX6 in the treatment of advanced gastric cancer
ZL-2301 (Brivanib)
Hepatocellular Carcinoma
The efficacy, safety and pharmacokinetics of ZL-2301 in advanced liver cancer
For more information about the above trials, please visit http://www.chinadrugtrials.org.cn/
友情链接:凤凰彩票app  快乐8注册用户名  快乐8平台注册账号  多米彩票官网  幸运时时彩官网  yy彩票官网  澳洲幸运5  幸运8登录  极速飞艇登录平台  一分快3彩票注册平台